Applying Lipidomics to Non-Alcoholic Fatty Liver Disease: A Clinical Perspective

The prevalence of Non-alcoholic fatty liver disease (NAFLD) and associated complications, such as hepatocellular carcinoma (HCC), is growing worldwide, due to the epidemics of metabolic risk factors, such as obesity and type II diabetes. Among other factors, an aberrant lipid metabolism represents a...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Jian, Sigon, Giordano, Mullish, Benjamin H., Wang, Dan, Sharma, Rohini, Manousou, Pinelopi, Forlano, Roberta
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10143024/
https://www.ncbi.nlm.nih.gov/pubmed/37111211
http://dx.doi.org/10.3390/nu15081992
_version_ 1785033752776278016
author Huang, Jian
Sigon, Giordano
Mullish, Benjamin H.
Wang, Dan
Sharma, Rohini
Manousou, Pinelopi
Forlano, Roberta
author_facet Huang, Jian
Sigon, Giordano
Mullish, Benjamin H.
Wang, Dan
Sharma, Rohini
Manousou, Pinelopi
Forlano, Roberta
author_sort Huang, Jian
collection PubMed
description The prevalence of Non-alcoholic fatty liver disease (NAFLD) and associated complications, such as hepatocellular carcinoma (HCC), is growing worldwide, due to the epidemics of metabolic risk factors, such as obesity and type II diabetes. Among other factors, an aberrant lipid metabolism represents a crucial step in the pathogenesis of NAFLD and the development of HCC in this population. In this review, we summarize the evidence supporting the application of translational lipidomics in NAFLD patients and NAFLD associated HCC in clinical practice.
format Online
Article
Text
id pubmed-10143024
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-101430242023-04-29 Applying Lipidomics to Non-Alcoholic Fatty Liver Disease: A Clinical Perspective Huang, Jian Sigon, Giordano Mullish, Benjamin H. Wang, Dan Sharma, Rohini Manousou, Pinelopi Forlano, Roberta Nutrients Review The prevalence of Non-alcoholic fatty liver disease (NAFLD) and associated complications, such as hepatocellular carcinoma (HCC), is growing worldwide, due to the epidemics of metabolic risk factors, such as obesity and type II diabetes. Among other factors, an aberrant lipid metabolism represents a crucial step in the pathogenesis of NAFLD and the development of HCC in this population. In this review, we summarize the evidence supporting the application of translational lipidomics in NAFLD patients and NAFLD associated HCC in clinical practice. MDPI 2023-04-20 /pmc/articles/PMC10143024/ /pubmed/37111211 http://dx.doi.org/10.3390/nu15081992 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Huang, Jian
Sigon, Giordano
Mullish, Benjamin H.
Wang, Dan
Sharma, Rohini
Manousou, Pinelopi
Forlano, Roberta
Applying Lipidomics to Non-Alcoholic Fatty Liver Disease: A Clinical Perspective
title Applying Lipidomics to Non-Alcoholic Fatty Liver Disease: A Clinical Perspective
title_full Applying Lipidomics to Non-Alcoholic Fatty Liver Disease: A Clinical Perspective
title_fullStr Applying Lipidomics to Non-Alcoholic Fatty Liver Disease: A Clinical Perspective
title_full_unstemmed Applying Lipidomics to Non-Alcoholic Fatty Liver Disease: A Clinical Perspective
title_short Applying Lipidomics to Non-Alcoholic Fatty Liver Disease: A Clinical Perspective
title_sort applying lipidomics to non-alcoholic fatty liver disease: a clinical perspective
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10143024/
https://www.ncbi.nlm.nih.gov/pubmed/37111211
http://dx.doi.org/10.3390/nu15081992
work_keys_str_mv AT huangjian applyinglipidomicstononalcoholicfattyliverdiseaseaclinicalperspective
AT sigongiordano applyinglipidomicstononalcoholicfattyliverdiseaseaclinicalperspective
AT mullishbenjaminh applyinglipidomicstononalcoholicfattyliverdiseaseaclinicalperspective
AT wangdan applyinglipidomicstononalcoholicfattyliverdiseaseaclinicalperspective
AT sharmarohini applyinglipidomicstononalcoholicfattyliverdiseaseaclinicalperspective
AT manousoupinelopi applyinglipidomicstononalcoholicfattyliverdiseaseaclinicalperspective
AT forlanoroberta applyinglipidomicstononalcoholicfattyliverdiseaseaclinicalperspective

Ejemplares similares